Foghorn Therapeutics
Lynne Parshall serves as a Board Member for multiple organizations, including Foghorn Therapeutics Inc., Ring Therapeutics, Repertoire Immune Medicines, and Ionis Pharmaceuticals, where Lynne chairs the Compliance Committee and has held various leadership roles since 1991. Additionally, Lynne is the Chief Executive Officer of Lyme Pinnacle, Inc. and has previously served as Board Chair for Akcea Therapeutics, overseeing its formation and IPO. Lynne's extensive experience includes strategic advisory services, senior executive roles at Ionis Pharmaceuticals, and a partnership at Cooley LLP, specializing in biotechnology. Lynne holds a Bachelor of Arts from Harvard University and a Juris Doctor from Stanford University.
This person is not in the org chart
This person is not in any offices
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.